0001209191-23-016507.txt : 20230306
0001209191-23-016507.hdr.sgml : 20230306
20230306185556
ACCESSION NUMBER: 0001209191-23-016507
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230306
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Monohon Ted
CENTRAL INDEX KEY: 0001606905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 23710505
MAIL ADDRESS:
STREET 1: C/O FANTEX, INC.
STREET 2: 330 TOWNSEND ST., SUITE 234
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quince Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 901024039
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cortexyme, Inc.
DATE OF NAME CHANGE: 20160104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-06
0
0001662774
Quince Therapeutics, Inc.
QNCX
0001606905
Monohon Ted
C/O QUINCE THERAPEUTICS, INC.
601 GATEWAY BLVD., SUITE 1250
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Accounting Officer & VP
Common Stock
2023-03-06
4
S
0
1871
0.98
D
27440
D
Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022.
/s/ Ted Monohon
2023-03-06